In the last trading session, 1.38 million shares of the MaxCyte Inc (NASDAQ:MXCT) were traded. Most recently the company’s share price was $2.65, and it changed around $0.05 or 1.92% from the last close, which brings the market valuation of the company to $280.97M. MXCT currently trades at a discount to its 52-week high of $5.26, offering almost -98.49% off that amount. The share price’s 52-week low was $2.21, which indicates that the current value has risen by an impressive 16.6% since then. We note from MaxCyte Inc’s average daily trading volume that its 10-day average is 0.76 million shares, with the 3-month average coming to 625.92K.
MaxCyte Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended MXCT as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. MaxCyte Inc is expected to report earnings per share of -0.11 for the current quarter.
MaxCyte Inc (NASDAQ:MXCT) trade information
Instantly MXCT has showed a green trend with a performance of 1.92% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.74 on recent trading dayincreased the stock’s daily price by 3.28%. The company’s shares are currently down -36.30% year-to-date, but still up 13.73% over the last five days. On the other hand, MaxCyte Inc (NASDAQ:MXCT) is -18.71% down in the 30-day period. We can see from the shorts that 3.29 million shares have been sold at a short interest cover period of 4.46 day(s).
The consensus price target as assigned by Wall Street analysts is $6, which translates to bulls needing to increase their stock price by 55.83% from its current value. Analyst projections state that MXCT is forecast to be at a low of $6 and a high of $6.
MaxCyte Inc (MXCT) estimates and forecasts
The year-over-year growth rate is expected to be 7.14%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 9.05M in revenue for the current quarter. 5 analysts expect MaxCyte Inc to make 9.77M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 11.34M and 10.43M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -20.20%. Forecasts for the next quarter put sales growth at -6.32%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -11.37%. MaxCyte Inc earnings are expected to increase by 10.51% in 2025, but the outlook is positive 7.37% per year for the next five years.
MXCT Dividends
MaxCyte Inc’s next quarterly earnings report is expected to be released on 2025-Mar-10.
MaxCyte Inc (NASDAQ:MXCT)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.56% of MaxCyte Inc shares, and 73.87% of them are in the hands of institutional investors. The stock currently has a share float of 75.04%. MaxCyte Inc stock is held by 179.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 7.7814% of the shares, which is about 8.14 million shares worth $31.92 million.
CADIAN CAPITAL MANAGEMENT, LP, with 7.285% or 7.62 million shares worth $29.88 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
